Burch, Jane; Griffin, Susan; McKenna, Claire; Walker, Simon - In: PharmacoEconomics 30 (2012) 11, pp. 991-1004
Following a licence extension to include those aged 6–11 years, the National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis Pharmaceuticals UK) to submit evidence for the clinical and cost effectiveness of this drug for patients with severe...